Sort   by:  
 Page size 
MetabolomicsEx-Vivo Equine Cartilage Explant Osteoarthritis Model - A Metabolomics and Proteomics Study
Osteoarthritis (OA) is an age-related degenerative musculoskeletal disease characterised by loss of articular cartilage, synovitis, abnormal bone proliferation and subchondral bone sclerosis. Underlying OA pathogenesis is yet to be fully elucidated with no OA specific biomarkers in clinical use. Ex-...
2020-09-30 | MTBLS1495 | MetaboLights
ProteomicsCMTM6 suppresses cell-surface expression of death receptor FAS in mice but not in humans - human CMTM6 interactome
The transmembrane protein CMTM6 promotes plasma membrane expression of immune checkpoint PD-L1, an important suppressor of anti-tumor immunity. Targeting of CMTM6 was proposed as a strategy to decrease surface PD-L1 and trigger cytotoxicity against tumors. In accord, ablation of CMTM6 in mouse cance...
ORGANISM(S): Mus musculus (Mouse) 
2026-03-16 | PXD070359 | Pride
Cd58 Cmtm6 
ProteomicsCMTM6 suppresses cell-surface expression of death receptor FAS in mice but not in humans - mouse FAS interactome
The transmembrane protein CMTM6 promotes plasma membrane expression of immune checkpoint PD-L1, an important suppressor of anti-tumor immunity. Targeting of CMTM6 was proposed as a strategy to decrease surface PD-L1 and trigger cytotoxicity against tumors. In accord, ablation of CMTM6 in mouse cance...
ORGANISM(S): Mus musculus (Mouse) 
2026-03-16 | PXD070298 | Pride
Fas Cmtm6 Cd95 
ProteomicsCMTM6 suppresses cell-surface expression of death receptor FAS in mice but not in humans - mouse CMTM3-8 interactome
The transmembrane protein CMTM6 promotes plasma membrane expression of immune checkpoint PD-L1, an important suppressor of anti-tumor immunity. Targeting of CMTM6 was proposed as a strategy to decrease surface PD-L1 and trigger cytotoxicity against tumors. In accord, ablation of CMTM6 in mouse cance...
ORGANISM(S): Mus musculus (Mouse) 
2026-03-16 | PXD070246 | Pride
Cmtm3 Fas Cmtm8 Cmtm7 Cmtm6 Cmtm5 Cmtm4 Cd95 
UnknownImmunoPET: IMaging of cancer imMUNOtherapy targets with positron Emission Tomography: a phase 0/1 study characterising PD-L1 with 89Zr-durvalumab (MEDI4736) PET/CT in stage III NSCLC patients receiving chemoradiation study protocol.
Not available
S-EPMC9677006 | biostudies-literature
TranscriptomicsTranscriptional profiling of human olfactory neurosphere-derived cell lines from healthy and idiopathic Parkinsons disease individuals.
The human olfactory epithelium represents a readily accessible source of adult neural cell types which can be propagated in vitro. We have used this feature to establish olfactory neurosphere-derived (hONS) cells lines from patients with idiopathic Parkinson's disease (PD) and healthy controls. We i...
ORGANISM(S): Homo sapiens 
2011-07-14 | E-TABM-879 | biostudies-arrayexpress
UnknownEfficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma.
Not available
S-EPMC10582968 | biostudies-literature
MetabolomicsMetabolome and proteome changes in skeletal muscle and blood of pre-weaning calves fed leucine and threonine supplemented diets

In pre-weaning calves, both leucine and threonine play important roles in growth and muscle metabolism. In this study, metabolomics, proteomics and clinical chemistry were used to assess the effects of leucine and threonine supplementation added to milk replacer on 14 newborn Holstein male calves...

2020-02-20 | MTBLS1045 | MetaboLights
UnknownIsatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis.
Not available
S-EPMC7862055 | biostudies-literature
UnknownA phase I study of the OX40 agonist BGB-A445 with or without tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors: dose-escalation results.
Not available
S-EPMC12507935 | biostudies-literature
Sort   by:  
 Page size